Literature DB >> 6847029

Metabolic consequences of antihypertensive therapy.

W Flamenbaum.   

Abstract

The availability of pharmacologic agents has contributed to a reduction in the morbidity and mortality of hypertensive cardiovascular disease. However, antihypertensive agents are associated with changes that may adversely affect patients receiving therapy. Nutritional and metabolic consequences of antihypertensive therapy may be associated with enhanced atherosclerosis. The abnormalities in lipid metabolism, carbohydrate tolerance, and changes in the renin-angiotensin-aldosterone axis are reviewed. The mechanisms by which antihypertensive therapy causes these complications are unknown and their exact role in hypertensive cardiovascular disease remains to be elucidated. Appropriate selection of therapeutic agents and dietary manipulations may minimize the metabolic and nutritional consequences of antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847029     DOI: 10.7326/0003-4819-98-5-875

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

Authors:  H Dieplinger; P Y Schoenfeld; C J Fielding
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

2.  Abnormalities of carbohydrate metabolism in spontaneously hypertensive rats.

Authors:  W H Hörl; R M Schaefer; A Heidland
Journal:  Klin Wochenschr       Date:  1988-09-15

3.  Relation of serum calcium concentration to metabolic risk factors for cardiovascular disease.

Authors:  L Lind; S Jakobsson; H Lithell; B Wengle; S Ljunghall
Journal:  BMJ       Date:  1988-10-15

4.  Elevated serum uric acid--a facet of hyperinsulinaemia.

Authors:  M Modan; H Halkin; A Karasik; A Lusky
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

Review 5.  First-line treatment in hypertension. Role of perindopril.

Authors:  A Zanchetti
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  Propranolol versus labetalol: interesting differences in efficacy.

Authors:  W Flamenbaum
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

Review 7.  Antihypertensive therapy. Is it different in the elderly?

Authors:  F H Messerli
Journal:  Drugs       Date:  1990       Impact factor: 9.546

8.  Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension.

Authors:  M Modan; A Karasik; H Halkin; Z Fuchs; A Lusky; A Shitrit; B Modan
Journal:  Diabetologia       Date:  1986-02       Impact factor: 10.122

9.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.

Authors:  M Modan; H Halkin; S Almog; A Lusky; A Eshkol; M Shefi; A Shitrit; Z Fuchs
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.